Search
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigationalTeclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. … [A253587] Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug to recruit CD3-expressing T cells to BCMA-expressing
Cytisine
go.drugbank.com/drugs/DB09028InvestigationalRecent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy. … Cytisine is an alkaloid naturally derived from the Fabaceae family of plants including the genera Laburnum and Cytisus.
Categories: Drugs Used in Addictive Disorders, Drugs Used in Nicotine DependenceTegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedIt was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA. … Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4.
Droxidopa
go.drugbank.com/drugs/DB06262ApprovedInvestigationalDroxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. … Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout
Categories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor AgonistsPlerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigational[A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678] … Since CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment, blocking this interaction leads to an increase in CD34+ cell circulating levels.
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAbrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). … including biologics, or when the use of those therapies is inadvisable.
Magaldrate
go.drugbank.com/drugs/DB08938ApprovedInvestigationalWithdrawnMagaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Mixtures: M A L D I MBerahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalThis combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications … It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection.
Piperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalPiperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China [A31550]. … It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label].
Nabilone
go.drugbank.com/drugs/DB00486ApprovedInvestigationalCB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function [A32676]. … This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.
Products: Ran-nabilone